Pharma & Bio
Technology
Cellbion Co., Ltd. Rises on Renewed Interest in Prostate Cancer Clinical Trial… HanmiPharm Also Up 5% on Weight-Loss Drug Launch [Bio Spotlight]
On the 29th, the domestic pharmaceutical, biotech, and healthcare stock market rose, driven by individual catalysts such as clinical data, expanded indications, and new product launches. #Cellbion Co.…
- 2026-10-31 07:07:06
- Minji Son
Technology
CellBion Rises on Renewed Interest in Prostate Cancer Data; Hanmi Pharma Gains 5% on Obesity Drug Launch [K-Bio Pulse]
On Oct. 29, South Korean pharmaceutical, biotech, and healthcare stocks rose on company-specific developments, including clinical data, expanded treatment indications, and new product launches. CellBi…
- 2026-10-31 07:07:05
- Minji Son
Lifestyle
[ESMO 2026] Professor Jo Byung-cheol of Yonsei Cancer Hospital: “Skin Side Effects from Lecraz Combination Therapy Can Be Managed… Treatment Discontinuations Will Decrease”
“In the combination therapy of Lecraz and Librivant, most skin-related side effects occurred predominantly during the initial 12 weeks—that is, within the first three months—of treatment. Once this pe…
- 2026-10-31 07:01:03
- Kim Jinsoo
Lifestyle
Diverging Market Sentiment: Capital Flows to Proven Performers as Medical Robotics Surge [K-Bio Pulse]
As the domestic stock market navigates a mixed consolidation phase, a sharp divergence in performance is emerging across the pharmaceutical, biotechnology, and medical device sectors. Rather than chas…
- 2026-10-30 07:21:03
- YU JIN-HEE
Lifestyle
Mixed Investor Sentiment Leads to Focus on Winning Sectors… Medical Robots on the Rise [Bio Spotlight]
As the domestic stock market continues to show mixed trends recently, the pharmaceutical, biotech, and medical device (hereinafter “bio”) sectors are also experiencing mixed fortunes. Investment capit…
- 2026-10-30 07:21:03
- YU JIN-HEE
Technology
ROKIT HEALTHCARE Inc. Cites ‘Harvard and U.S. Academic Societies’… Claims 62.5% Effectiveness, but Evidence Remains Unrevealed
#ROKIT HEALTHCARE Inc. presented the results of preclinical studies on its kidney regeneration patch at the American Society of Nephrology, but the key figures were identical to the interim results re…
- 2026-10-30 07:11:02
- KIM SAE-MI
Technology
“GLP-1 Results Disappointing”… What’s Really on the Mind of the Obesity Drug Developer?
“Disappointing Interim Results for GLP-1 Drug Therapy.”This was the headline on a promotional brochure distributed by Donga ST(170900)at the Severe Diabetes Symposium held on the 15th at the COEX Mago…
- 2026-10-30 07:06:02
- KIM SUNG-JIN
Lifestyle
[ESMO 2026] Kim Dong-geon, CEO of Eleva: “U.S. Pricing for Ripicto to Be Finalized Within the Year… Premium Strategy to Be Pursued”
“We plan to finalize the U.S. launch price for Rifictu (Lirapugratinib) by the end of this year. We are consulting with key stakeholders, including insurers and pharmacy benefit managers (PBMs), regar…
- 2026-10-30 06:01:04
- Kim Jinsoo
Lifestyle
Y2 Solution’s U.S.-based Luxa Maintains Efficacy in Long-Term Follow-Up Study of Age-Related Macular Degeneration Treatment... Technology Export Expected to Gain Momentum
The U.S. joint venture of Y2 Solution(011690)has released groundbreaking data on long-term efficacy in the field of cell therapies for dry age-related macular degeneration (AMD), an area that has long…
- 2026-10-29 12:48:02
- YU JIN-HEE
Technology
OliX Slides…What’s Next for OLX301A? [K-Bio Pulse]
Korean stocks rebounded on October 27, but several biotech stocks suffered a “Black Tuesday.” The KOSPI rose 3.09% to 5,638.34, and the KOSDAQ gained 2.29% to 743.83. A buy-side sidecar temporarily su…
- 2026-10-29 07:42:03
- NA EUN-KYUNG
PHARM EDAILY
Shorts